AGP Executive Report
Last update: 4 hours agoInternational Health Cover: Liechtenstein-based insurer Squarelife is backing an expanded Genki Native plan for expats and digital nomads, now available from one month and with broader preventive and dental cover. Cancer Treatment: First European patients have received ImmunityBio’s bladder cancer therapy Anktiva in Germany and Austria. Its EU approval also covers Liechtenstein. Medicine Safety: The European Medicines Agency is reviewing depression and anxiety drug Deanxit after reports of serious movement, memory and thinking problems, some persisting after treatment stopped. Local Health Policy: Abortion remains largely illegal in Liechtenstein after Hereditary Prince Alois vetoed a bill that would have allowed first-trimester terminations. Antifungal Treatment: Strong European sales of Cresemba, used for serious fungal infections, triggered a $37.5 million payment to its Swiss developer; the medicine is approved in Liechtenstein.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.